N-[2-(4-nitrophenyl)acetyl]methanesulfonamide | 402508-74-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(4-nitrophenyl)acetyl]methanesulfonamide
• 英文别名: N-(methylsulfonyl)-2-(4-nitrophenyl)acetamide；N-methylsulfonyl-2-(4-nitrophenyl)acetamide
• CAS: 402508-74-1
• 化学式: C₉H₁₀N₂O₅S
• 分子量: 258.255
• InChiKey: CECPIYUBNKRQJS-UHFFFAOYSA-N

物化性质

• 熔点：
  191-193 °C
• 密度：
  1.454±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  117
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[2-(4-nitrophenyl)acetyl]methanesulfonamide 在 盐酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 、 水 为溶剂， 以91.7%的产率得到2-(4-氨基苯基)-N-(甲基磺酰基)乙酰胺
  参考文献：
  名称：

  吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用

  摘要：

  本发明提供了式(I)所示的一类吡唑并嘧啶化合物或其药学可接受的盐及其制备方法和在制备治疗或预防癌症的药物中的应用。该类化合物是PI3K抑制剂，具有优异的抑制活性，有望用于多种恶性肿瘤的治疗。

  公开号：

  CN110950868B
• 作为产物：
  描述：

  甲基磺酰胺 、 对硝基苯乙酸 在 N,N'-羰基二咪唑 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以59.7%的产率得到N-[2-(4-nitrophenyl)acetyl]methanesulfonamide
  参考文献：
  名称：

  吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用

  摘要：

  本发明提供了式(I)所示的一类吡唑并嘧啶化合物或其药学可接受的盐及其制备方法和在制备治疗或预防癌症的药物中的应用。该类化合物是PI3K抑制剂，具有优异的抑制活性，有望用于多种恶性肿瘤的治疗。

  公开号：

  CN110950868B

文献信息

• [EN] PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG<br/>[FR] COMPOSÉ DE PYRAZOLOPYRIMIDINE ET SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION DANS LA PRÉPARATION D'UN MÉDICAMENT ANTICANCÉREUX<br/>[ZH] 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
  申请人：SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD

  公开号：WO2020063636A1

  公开（公告）日：2020-04-02

  本发明提供了式(I)所示的一类吡唑并嘧啶化合物或其药学可接受的盐及其制备方法和在制备治疗或预防癌症的药物中的应用。该类化合物是新型的PI3K抑制剂，具有优异的抑制活性，有望用于多种恶性肿瘤的治疗。
• Synthesis and Evaluation of Potent and Selective β₃ Adrenergic Receptor Agonists Containing Acylsulfonamide, Sulfonylsulfonamide, and Sulfonylurea Carboxylic Acid Isosteres
  作者：David E. Uehling、Kelly H. Donaldson、David N. Deaton、Clifton E. Hyman、Elizabeth E. Sugg、David G. Barrett、Robert G. Hughes、Barbara Reitter、Kim K. Adkison、Mary E. Lancaster、Frank Lee、Robert Hart、Mark A. Paulik、Bryan W. Sherman、Timothy True、Conrad Cowan

  DOI：10.1021/jm0101500

  日期：2002.1.1

  Starting from phenethanolamine aniline leads 3a and 3b, we have identified a series of functionally potent and selective beta(3) adrenergic receptor (AR) agonists containing acylsulfonamide, sulfonylsulfonamide, or sulfonylurea groups within the aniline phenethanolamine series. In beta(3) beta(2), and beta(1) AR cAMP functional assays, 3a and other right-hand side (RHS) carboxylate analogues were found to be full agonists that were modestly selective against beta(1) or beta(2) ARs, while analogues lacking RHS acid functionality were active at beta(3) AR but not selective. Replacement of the carboxylate with acylthiazole and acylmethylsulfone gave potent, but only modestly selective, compounds. Increasing the size of the RHS sulfonamide substituent with phenyl or p-toluene afforded compounds with good potency and functional selectivity (beta(3) AR pEC(50) greater than 8; beta(1) and beta(2) AR selectivity greater than 40- and 500-fold, respectively). Our SAR studies suggest that the potency and selectivity profile of the best analogues reported here is a result of both the steric bulk and acidity of the RHS sulfonamide NH group. Although all of the analogues had a pharmacokinetic half-life of less than 2 h, acylsulfonamides 43 and 44 did show moderately low clearance in dogs. These two compounds were further evaluated by thermographic imaging in mice and were found to produce a robust thermogenic response via oral administration.
• PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG
  申请人：SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD.

  公开号：US20210340146A1

  公开（公告）日：2021-11-04

  Provided in the present disclosure is a type of pyrazolopyrimidine compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method thereof and the use of same in the preparation of a drug for treating or preventing cancers. Such a compound is a new-type PI3K inhibitor and has an excellent inhibitory activity, and can hopefully be used for treating a variety of malignant tumors.